Walter S. Woltosz Sells 20,000 Shares of Simulations Plus, Inc. (NASDAQ:SLP) Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $27.66, for a total transaction of $553,200.00. Following the transaction, the director now directly owns 3,462,584 shares of the company’s stock, valued at approximately $95,775,073.44. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Simulations Plus Stock Up 4.0 %

Shares of NASDAQ SLP opened at $28.60 on Wednesday. Simulations Plus, Inc. has a twelve month low of $27.22 and a twelve month high of $51.22. The firm has a market cap of $574.00 million, a PE ratio of 58.37 and a beta of 0.71. The business has a fifty day simple moving average of $31.93 and a two-hundred day simple moving average of $39.66.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same period in the previous year, the company posted $0.18 earnings per share. The firm’s quarterly revenue was up 19.9% on a year-over-year basis. On average, research analysts expect that Simulations Plus, Inc. will post 1.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday. KeyCorp initiated coverage on Simulations Plus in a report on Monday, July 29th. They set an “overweight” rating and a $47.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Thursday, October 24th. JMP Securities started coverage on Simulations Plus in a research report on Tuesday, July 16th. They set a “market perform” rating for the company. Finally, BTIG Research cut their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Simulations Plus presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Hedge Funds Weigh In On Simulations Plus

Hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. lifted its holdings in Simulations Plus by 2.6% during the third quarter. Principal Financial Group Inc. now owns 87,273 shares of the technology company’s stock worth $2,794,000 after buying an additional 2,226 shares during the period. US Bancorp DE raised its position in shares of Simulations Plus by 37.0% in the 3rd quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock worth $159,000 after acquiring an additional 1,343 shares in the last quarter. Congress Asset Management Co. lifted its stake in shares of Simulations Plus by 22.5% during the 3rd quarter. Congress Asset Management Co. now owns 206,542 shares of the technology company’s stock worth $6,613,000 after purchasing an additional 37,914 shares during the last quarter. Semanteon Capital Management LP bought a new stake in Simulations Plus during the third quarter valued at about $358,000. Finally, Tributary Capital Management LLC grew its stake in Simulations Plus by 54.7% in the third quarter. Tributary Capital Management LLC now owns 325,567 shares of the technology company’s stock valued at $10,425,000 after purchasing an additional 115,122 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.